Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589467815> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2589467815 endingPage "310" @default.
- W2589467815 startingPage "310" @default.
- W2589467815 abstract "310 Background: A higher initial metabolic tumor burden is associated with lower median survival in locally advanced pancreatic cancer (LAPC), yet the prognostic utility of PET/CT is not defined in the setting of borderline resectable pancreatic cancer (BRPC). Methods: We performed a retrospectivereview of our institutional experience treating BRPC. Initial staging included endoscopic ultrasound as well as pancreatic protocol CT and PET/CT scans. All patients underwent neoadjuvant gemcitabine-based chemotherapy and radiation therapy (RT). RT was delivered using standard fractionation intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT). Restaging CT and PET/CT scans were obtained approximately 4 weeks following RT completion. We measured the significance of the pre-treatment and post-treatment SUV maximum and metabolic tumor volume (MTV) 2.5 to 5.0, which was defined as the MTV above a threshold SUV of 2.5, 3.0, 4.0 and 5.0. Cox regression models were used to evaluate the significance between these parameters and disease free survival (DFS) and overall survival (OS). Results: We evaluated a total of 72 BRPC patients. Median follow up was 12.7 months. 56 patients (77%) received induction chemotherapy with gemcitabine, docetaxel and capecitabine (GTX). 43 (59.7 %) underwent surgical resection. Significant predictors for OS in the whole cohort included pre-treatment SUV maximum (p=0.0042), post-treatment SUV maximum (p=0.0183), pre-treatment MTV 2.5 (p=0.0016) and pre-treatment MTV 4.0 (p=0.0111). In addition, the difference between the MTV 4.0 pre-treatment and post-treatment was significant (p=0.0285). In patients who underwent surgical resection, there was a significant correlation between OS with pre-treatment SUV max (p=0.0229) and post-treatment SUV maximum (p=0.0325) but not pre-treatment MTV 2.5 (p=0.0654) nor MTV 4.0 (p=0.0928) nor the differences between each variable pre (0.1482) or post-treatment (0.0959). Conclusions: This is the first study to suggest that pre and post treatment PET activity is prognostic for BRPC." @default.
- W2589467815 created "2017-03-03" @default.
- W2589467815 creator A5000451156 @default.
- W2589467815 creator A5005757836 @default.
- W2589467815 creator A5006838528 @default.
- W2589467815 creator A5012399386 @default.
- W2589467815 creator A5029172370 @default.
- W2589467815 creator A5029626497 @default.
- W2589467815 creator A5035589941 @default.
- W2589467815 creator A5044354357 @default.
- W2589467815 creator A5047712976 @default.
- W2589467815 creator A5052124202 @default.
- W2589467815 creator A5062142011 @default.
- W2589467815 creator A5067278346 @default.
- W2589467815 date "2013-02-01" @default.
- W2589467815 modified "2023-09-23" @default.
- W2589467815 title "Pretreatment metabolic tumor volume (MTV) as a predictor of survival in borderline resectable pancreatic cancers treated with neoadjuvant therapy." @default.
- W2589467815 doi "https://doi.org/10.1200/jco.2013.31.4_suppl.310" @default.
- W2589467815 hasPublicationYear "2013" @default.
- W2589467815 type Work @default.
- W2589467815 sameAs 2589467815 @default.
- W2589467815 citedByCount "0" @default.
- W2589467815 crossrefType "journal-article" @default.
- W2589467815 hasAuthorship W2589467815A5000451156 @default.
- W2589467815 hasAuthorship W2589467815A5005757836 @default.
- W2589467815 hasAuthorship W2589467815A5006838528 @default.
- W2589467815 hasAuthorship W2589467815A5012399386 @default.
- W2589467815 hasAuthorship W2589467815A5029172370 @default.
- W2589467815 hasAuthorship W2589467815A5029626497 @default.
- W2589467815 hasAuthorship W2589467815A5035589941 @default.
- W2589467815 hasAuthorship W2589467815A5044354357 @default.
- W2589467815 hasAuthorship W2589467815A5047712976 @default.
- W2589467815 hasAuthorship W2589467815A5052124202 @default.
- W2589467815 hasAuthorship W2589467815A5062142011 @default.
- W2589467815 hasAuthorship W2589467815A5067278346 @default.
- W2589467815 hasConcept C121608353 @default.
- W2589467815 hasConcept C126322002 @default.
- W2589467815 hasConcept C126838900 @default.
- W2589467815 hasConcept C143998085 @default.
- W2589467815 hasConcept C146357865 @default.
- W2589467815 hasConcept C151730666 @default.
- W2589467815 hasConcept C2776694085 @default.
- W2589467815 hasConcept C2777909004 @default.
- W2589467815 hasConcept C2778292576 @default.
- W2589467815 hasConcept C2780210213 @default.
- W2589467815 hasConcept C2780258809 @default.
- W2589467815 hasConcept C2781190966 @default.
- W2589467815 hasConcept C2989005 @default.
- W2589467815 hasConcept C509974204 @default.
- W2589467815 hasConcept C526805850 @default.
- W2589467815 hasConcept C530470458 @default.
- W2589467815 hasConcept C71924100 @default.
- W2589467815 hasConcept C86803240 @default.
- W2589467815 hasConceptScore W2589467815C121608353 @default.
- W2589467815 hasConceptScore W2589467815C126322002 @default.
- W2589467815 hasConceptScore W2589467815C126838900 @default.
- W2589467815 hasConceptScore W2589467815C143998085 @default.
- W2589467815 hasConceptScore W2589467815C146357865 @default.
- W2589467815 hasConceptScore W2589467815C151730666 @default.
- W2589467815 hasConceptScore W2589467815C2776694085 @default.
- W2589467815 hasConceptScore W2589467815C2777909004 @default.
- W2589467815 hasConceptScore W2589467815C2778292576 @default.
- W2589467815 hasConceptScore W2589467815C2780210213 @default.
- W2589467815 hasConceptScore W2589467815C2780258809 @default.
- W2589467815 hasConceptScore W2589467815C2781190966 @default.
- W2589467815 hasConceptScore W2589467815C2989005 @default.
- W2589467815 hasConceptScore W2589467815C509974204 @default.
- W2589467815 hasConceptScore W2589467815C526805850 @default.
- W2589467815 hasConceptScore W2589467815C530470458 @default.
- W2589467815 hasConceptScore W2589467815C71924100 @default.
- W2589467815 hasConceptScore W2589467815C86803240 @default.
- W2589467815 hasIssue "4_suppl" @default.
- W2589467815 hasLocation W25894678151 @default.
- W2589467815 hasOpenAccess W2589467815 @default.
- W2589467815 hasPrimaryLocation W25894678151 @default.
- W2589467815 hasRelatedWork W1988326884 @default.
- W2589467815 hasRelatedWork W2004396656 @default.
- W2589467815 hasRelatedWork W2080820783 @default.
- W2589467815 hasRelatedWork W2085123446 @default.
- W2589467815 hasRelatedWork W2095704084 @default.
- W2589467815 hasRelatedWork W2245783872 @default.
- W2589467815 hasRelatedWork W2315587357 @default.
- W2589467815 hasRelatedWork W2419408601 @default.
- W2589467815 hasRelatedWork W2999731264 @default.
- W2589467815 hasRelatedWork W3029364823 @default.
- W2589467815 hasVolume "31" @default.
- W2589467815 isParatext "false" @default.
- W2589467815 isRetracted "false" @default.
- W2589467815 magId "2589467815" @default.
- W2589467815 workType "article" @default.